Holding the Line in AML: Real-World Care Meets Breakthrough Trials
The HemOnc Pulse
00:00
Choosing between menin inhibitors
Wang compares ziftomenib and revumenib, noting approvals, QTc risks, interactions, dosing, and formulary value.
Play episode from 07:44
Transcript
